A Phase III, Double-blind, Randomized, Placebo Controlled Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated Infants
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The study will compare the transmissible levels of poliovirus type-2 detected in stool samples collected at the time of the nOPV2 challenge and subsequent timepoints in 3 groups of newborns receiving an nOPV2 dose at birth and primed with 3 doses of IPV (6 - 10 - 14 weeks of age).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 1 day
Maximum Age: 7 days
Healthy Volunteers: t
View:
• Newborn infants of maximum 1 week of age with birth weight \> 2,500 g.
• Healthy infants without obvious medical conditions like immunodeficiency diseases, severe congenital malformations, severe neurological diseases or any other disease that require high doses of corticosteroids or immunotherapies that preclude the subject from participating in the study as established by medical history and physical examination.
• Written informed consent obtained from both parents or legal guardian(s) as per country regulations.
• Resides in the area and parents willing to adhere to all study procedures.
Locations
Other Locations
Bangladesh
icddr,b - Matlab Health Research Centre
RECRUITING
Chāndpur
Contact Information
Primary
Ricardo Rüttimann, Dr.
rruttimann@fidec-online.org
+54 9 11 6118-8536
Backup
Gabriela Aguirre
gaguirre@fidec-online.org
+54 911 5964 7383
Time Frame
Start Date:2026-04-30
Estimated Completion Date:2027-03-08
Participants
Target number of participants:740
Treatments
Experimental: nOPV2 at birth
Approximately 330 subjects to receive 1 dose of nOPV2 at birth followed by a regular IPV schedule at approx. 6, 10, 14 weeks of age and an nOPV2-002 challenge at approx. 18 weeks of age.
Experimental: nOPV2 at birth and Wk 14 of age
Approximately 80 subjects to receive 2 doses of nOPV2 at birth and 14 wks of age plus a regular IPV schedule at approx. 6, 10, 14 weeks of age and an nOPV2-002 challenge at approx. 18 weeks of age.
Placebo_comparator: Placebo
Approximately 330 subjects to receive 2 doses of placebo at birth and 14 wks of age plus a regular IPV schedule at approx. 6, 10, 14 weeks of age and an nOPV2-002 challenge at approx. 18 weeks of age